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Abstract
Background: The Bladder Cancer Index (BCI) and Functional Assessment of Cancer Therapy-Bladder-Cystectomy
(FACT-Bl-Cys) were developed to measure disease-specific health-related quality of life (HRQOL) in bladder cancer
patients and patients treated with radical cystectomy, respectively. Both patient-reported outcome measures
(PROMs) are frequently used in clinical practice, but are not yet validated according to the COSMIN criteria and not
yet available in Dutch. Therefore, the aim of this study was to translate the BCI and FACT-Bl-Cys into Dutch and to
evaluate their measurement properties according to the COSMIN criteria.
Methods: The BCI and FACT-Bl-Cys were translated into Dutch using a forward-backward method, and
subsequently administered at baseline (pre-operatively) and 3 months post-operatively in bladder cancer patients
who received a radical cystectomy. Validity (content and construct), reliability (internal consistency, test-retest
reliability, and measurement error), floor and ceiling effects, and responsiveness were assessed according to the
COSMIN criteria.
Results: Forward-backward translation encountered no particular linguistic problems. In total 260 patients
completed the baseline measurement, while 182 patients completed the three-month measurement. Only a
ceiling effect was identified for the BCI. Hypotheses testing for construct validity was satisfying, as 67% and 92% of
the hypothesized correlations were confirmed. Structural validity was moderate for both measures, as confirmatory
factor analyses showed limited fit. Reliability of both PROMs was good. The intraclass correlation coefficient (ICC) of
the BCI domains ranged from 0.47 to 0.93, minimal value of Cronbach’s α was 0.70, smallest detectable change on
group level (SDC group) ranged from 1.9 to 8.6. The ICC of the FACT-Bl-Cys domains ranged from 0.43 to 0.83,
minimal value of Cronbach’s α was 0.77, SDC group was around 1. Only the FACT-Bl-Cys total score was found to
be responsive to changes in generic quality of life.
Conclusions: The Dutch versions of the BCI and FACT-Bl-Cys were shown to be reliable and have good content
validity. Structural validity was limited for both measures. Only the FACT-Bl-Cys total score was responsive to
changes in generic HRQOL. Despite some limitations, both PROMs seem suitable for use in clinical practice and
research.
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Introduction
Bladder cancer (BCa) ranks ninth in worldwide cancer
incidence and is one of the most expensive malignancies
to manage [1, 2]. The spectrum of BCa includes non-
muscle-invasive, muscle-invasive, and metastatic disease,
each with its own clinical behavior, prognosis, and
treatment.
Due to the heterogeneous BCa population, the various
treatments (e.g. transurethral surgery, chemotherapy, rad-
ical cystectomy), and the lack of long-term follow-up data,
not much is known regarding the patient burden imposed
by BCa [3–5]. Since BCa patients will usually undergo sev-
eral treatments, measuring health-related quality of life
(HRQOL) with valid instruments is important for clini-
cians and patients when making informed decisions about
treatments, based on patients’ experiences [6, 7]. Increas-
ingly more clinical trials [8] and comparative effectiveness
studies [9] include patient-reported outcomes (PROs), in
addition to objective outcomes.
In 2016, a systematic review was published in which
Danna et al. [10] advised to use the Functional Assess-
ment of Cancer Therapy-Bladder-Cystectomy (FACT-
Bl-Cys, formerly known as the FACT-VCI) [11, 12]
when studying HRQOL in patients undergoing radical
cystectomy and to use the Bladder Cancer Index (BCI)
[13, 14] when studying HRQOL in patients with non-
muscle-invasive or muscle-invasive BCa disease of any
stage. Authors report that the FACT-Bl-Cys was the
only available measure for muscle-invasive BCa patients
and the BCI has unique “bother” scales, which quantifies
the symptoms’ impact [10]. Both patient-reported
outcomes measures (PROMs) are frequently used and
have been translated into various languages (i.e. BCI is
available in Spanish, French, Hungarian [15–17], and
FACT-Bl-Cys is available in Korean and Swedish [18,
19]), but were not yet available in Dutch. In 2018,
Mason et al. revealed in a systematic review that most
PROMs related to BCa had limited information reported
on their measurement properties [4]. The FACT-Bl-Cys
and BCI are suggested to be most promising, but some
measurement properties (e.g. content validity, measure-
ment error, and responsiveness) are still unknown [4].
To assess whether both PROMs provide valuable infor-
mation in clinical practice and research, it is warranted to
study their measurement properties. The COnsensus-
based Standards for the selection of health Measurement
INstruments (COSMIN) checklist was developed to assess
the quality of validation studies and can be used to design
and report on these studies [20–22]. The aim of this study
was to translate the BCI and FACT-Bl-Cys into Dutch
and to evaluate the validity, reliability, floor and ceiling
effects, and responsiveness according to the COSMIN
criteria.
Methods
Translation procedure
The BCI and FACT-Bl-Cys were translated into Dutch,
using a forward–backward method according to published
guidelines, involving six steps [23, 24]. A schematic over-
view of the translation procedure is presented in Fig. 1.
First, two bilingual native Dutch translators independently
translated the United States English versions of the BCI
Fig. 1 Translation procedure
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and FACT-Bl-Cys into Dutch (forward translation). Sec-
ond, two independent native Dutch speakers (JG, CM)
reconciled the two forward translations into one forward
translation. Any uncertainties were discussed among JG,
CM and a urologist (CW), and resolved by consensus.
Third, one independent native English translator, who is
fluent in Dutch, translated the forward translation back to
English. The translator was uninformed of the concepts
explored and blinded to the original instruments. Fourth,
three independent bilingual experts (two native Dutch and
one native Flemish speaker, all fluent in English) reviewed
and commented on all documents (original version, for-
ward and backward translations). The synthesis process
was carefully documented and outcomes were evaluated
by three Dutch speakers (a language coordinator, JG,
CM). Conceptual rather than literal translation was lead-
ing, aiming to preserve the original meaning of each item.
This resulted in pre-final versions of the Dutch BCI and
FACT-Bl-Cys. Fifth, both pre-final versions were tested
during a pilot study, in which cognitive interviews were
carried out among 20 BCa patients who underwent a
radical cystectomy. Patients completed both pre-final
versions and were interviewed about the comprehension
of items and the chosen response, according to Functional
Assessment of Chronic Illness Therapy (FACIT) guideline
and instructions [24]. Patients were randomly recruited
from Radboud university medical center (Nijmegen, the
Netherlands) and Rijnstate Hospital (Arnhem, the
Netherlands). Finally, experts (JG, CM, CW, and FACIT
representatives) discussed the outcomes and final ver-
sions were realized to enable the evaluation of their
psychometrics.
Study design and sample
As part of the RACE study (trial identifying number
NTR5362, Dutch Trial Registry, www.trialregister.nl)
patients were asked to complete four measures (i.e. BCI,
FACT-Bl-Cys, EQ-5D-5 L, and EQ-VAS). Patients that
completed the three-month follow-up period were
included in this substudy. RACE is a comparative effect-
iveness study aiming to determine the (cost-)effectiveness
of robot-assisted and open radical cystectomy [25]. Radical
cystectomy is the standard treatment of non-metastatic,
invasive BCa and is curative in the majority of patients
with localized disease [1]. This surgery is associated with a
high complication rate, varying between 49% and 68%
[26]. Studies suggest that radical cystectomy affects urin-
ary, sexual and bowel function, and body image which can
lead to anxiety and depression [27–30].
All participants in this validation study fulfilled the
inclusion criteria of the RACE study: they were 18 years
or older, had an oncological indication for radical cystec-
tomy, a histologically proven primary muscle invasive
urothelial carcinoma or therapy resistant high-risk non
muscle-invasive BCa (CIS, refractair pTa-1), a non-meta-
static tumor (cT1a-cT4a, cN0M0), they were able to
complete Dutch questionnaires, and provided written in-
formed consent. Patients were excluded from RACE
when they met one of the following criteria: previous
major abdominal surgery (i.e. existing stomata, low an-
terior resection of the rectum or rectal amputation, sta-
tus after open aortabifemoral graft, status after right
hemicolectomy), pregnancy, morbid obesity (BMI ≥ 40
kg/m2), radical cystectomy performed in combination
with a nephrectomy or a partial colon resection.
Measures used in this validation study were the trans-
lated Dutch versions of the BCI and FACT-Bl-Cys, and
the validated Dutch versions of the EuroQol 5-Domain 5-
Level (EQ-5D-5 L) [31] and the EuroQol Visual Analogue
Scale (EQ-VAS). Participants could choose to complete
the PROMs on paper or electronically. Participants com-
pleted the PROMs at baseline (T0, pre-operatively) and 3
months post-operatively (T3). Patients who completed the
three-month measurement (T3) were asked to complete
the PROMs again within 2 weeks (T3 retest).
Measures
Bladder Cancer index (BCI)
The BCI is developed to measure disease-specific HRQOL
in patients with nonmuscle-invasive and muscle-invasive
BCa disease of any stage. It consists of 36 items covering
three domains: urinary (14 items), bowel (10 items), and
sexual (12 items) [13, 14]. Each domain consists of two
subdomains (function and bother). Item responses are
based on 4- or 5-point Likert scales; domain and subdo-
main scores are standardized to a 0–100 point scale where
higher scores indicate better HRQOL. No total BCI score
is calculated. Function items focus on the frequency of the
disease symptoms and bother items reflect the individual
perception of these symptoms. According to BCI scoring
instructions, the number of non-missing items needed to
compute domain scores varied from 10 (urinary domain
and sexual domain) to 4 (“urinary function”, “bowel func-
tion”, “sexual bother”), otherwise scores were set to
missing.
Functional assessment of Cancer therapy-bladder-
cystectomy (FACT-Bl-Cys)
The FACT-Bl-Cys is developed to measure condition-spe-
cific HRQOL in patients treated with radical cystectomy. It
consists of the four general FACT-General (FACT-G) [32]
domains (physical, social/family, emotional, and functional
well-being) plus one additional Bl-Cys domain (17 items)
covering urinary, sexual and bowel function, and body
image [11, 12]. Thus, the FACT-Bl-Cys measure consists of
five domains (physical, social/family, emotional, functional
well-being, and Bl-Cys). The measure consists of 44 items
and responses are based on 5-point Likert scales, with
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higher scores indicating better HRQOL. The total FACT-
Bl-Cys score can range from 0 to 168. According to FACT-
Bl-Cys scoring instructions, more than 50% of the items
per domain need to be answered in order to calculate a do-
main score.
Statistical analyses
COSMIN recommendations were used as a guide for
evaluating the measurement properties of the Dutch BCI
and FACT-Bl-Cys [22]. Validity, reliability, floor and
ceiling effects, and responsiveness were assessed as de-
scribed below. Analyses were performed using IBM SPSS
Statistics software (version 22.0, IBM Corp., Armonk,
NY, USA). Additionally, R version 3.5.2 (R Foundation
for Statistical Computing, Vienna, Austria), including
the packages mice (version 3.5.0) [33] and SemTools
(version 0.5–1.928) [34] was used for multiple imput-
ation and confirmatory factor analyses (CFA).
Because the BCI is developed for generic BCa patients,
we determined its measurement properties at baseline
(T0, pre-operatively), with the exception of test-retest
and measurement error which were based on T3 and T3
retest. The test-retest and measurement error could not
be assessed at T0, because there was no possibility to
distribute and complete the PROMs again within two
weeks since patients received a cystectomy on short
term after T0. Because the FACT-Bl-Cys is developed
for patients treated with radical cystectomy, we deter-
mined its measurement properties after the cystectomy
had been performed, i.e. at T3 and T3 retest.
Floor and ceiling effects
Floor and ceiling effects are considered to be present if
more than 15% of respondents achieved the lowest or
highest possible score, respectively [21, 35]. We evaluated
the presence of floor and ceiling effects of single scores in
this study to assess interpretability. Interpretability [20] is
the degree to which one can assign a qualitative meaning
on a quantitative score or change in score. Additionally,
floor and ceiling effects can also impact the responsiveness
(if scores cannot further improve or deteriorate) and valid-
ity of an instrument (as patients with the lowest or highest
possible score cannot be distinguished from each other).
Validity
Validity in this study was assessed by content validity
and construct validity [20]. Content validity was evalu-
ated from the perspective of researchers, patients, and
urologists. First, the component of content validity
known as face validity was determined by discussing
with the research team whether the two measures gave
the impression of adequately reflecting the construct to
be measured. Second, content validity was evaluated
during the above described cognitive interviews (n = 20).
An interview guide was used for the interviews and re-
spondents were invited to appraise the two measurement
instruments on relevance, comprehensiveness, and com-
prehensibility [36]. Input from the interviews was sum-
marized and notable similarities and differences in
opinion among respondents were registered and closely
evaluated in our research team.
Construct validity was evaluated by structural validity
and hypotheses testing. First, structural validity was
assessed by confirmatory factor analyses (CFA) to con-
firm the previously suggested dimensionality of both
PROMs [37]. Regarding BCI, the original validation
study [13] identified three primary domains (urinary,
bowel and sexual) and one translation study [16] re-
ported that data fitted to six subdomains (function and
bother). Therefore, in this study BCI items were hypoth-
esized to load on three or six factors. Regarding FACT-
Bl-Cys, the original validation study [11] identified three
factors in the Bl-Cys domain and one translation study
[18] reported that the Bl-Cys domain fitted on three
other factors. Therefore, the FACT-G (four domains:
physical, social/family, emotional, functional well-being)
was hypothesized to load on four factors and the individ-
ual Bl-Cys domain on two different three-factor struc-
tures. Which items are structured within which factor is
presented in Table 4.
For a CFA, COSMIN advises to use a sample size of 7
patients per item, with a minimum number of 100 pa-
tients [38]. Since our sample size was too small according
to the COSMIN criteria as cases with missing items are
not analyzed in a CFA (i.e. listwise deletion), we
performed multiple imputation by chained equations gen-
erating 25 independent imputation datasets. Data were
imputed at item level using a predictive mean matching
approach. CFA was performed on the imputed datasets.
Model fit was evaluated based on the Comparative Fit
Index (CFI), Tucker-Lewis index (TLI), Root Means
Square Error of Approximation (RMSEA), and Standard-
ized Root Mean Square Residual (SRMR). The criteria for
unidimensionality include CFI ≥ 0.95, TLI ≥ 0.95,
RMSEA≤0.06, and SRMR≤0.08 [39].
Second, we tested various hypotheses by analyzing the
association between the BCI domains and FACT-Bl-Cys
domains, using Pearson’s correlation coefficients. Coeffi-
cients were considered low (< 0.30), moderate (0.30–
0.69) or high (≥0.70). If ≥75% of the set number of
hypotheses were confirmed, the construct validity was
considered good [21]. Pre-specified hypotheses regarding
BCI at T0 were that: a) correlations among different 3
domains (urinary, bowel, sexual) are low as they measure
different constructs; b) correlations between the BCI do-
mains and FACT-G, EQ-5D-5 L, EQ-VAS are moderate,
due to differences between generic and disease-specific
instruments. Pre-specified hypotheses regarding FACT-
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Bl-Cys at T3 were that: a) correlations among 5 different
domains (physical, social/family, emotional, functional,
Bl-Cys) are moderate based on original validation studies
[11, 40]; b) correlation between the Bl-Cys domain and
EQ-5D-5 L is moderate; c) correlation between FACT-
Bl-Cys total score and the EQ-5D-5 L and EQ-VAS is
moderate, due to differences between generic and dis-
ease-specific instruments. For the BCI and FACT-Bl-Cys
there were 12 and 13 pre-specified hypotheses formu-
lated, respectively.
Reliability
Reliability was assessed by analyzing internal consistency,
test-retest reliability, and measurement error [20].
Internal consistency [20] of subscale items was mea-
sured using Cronbach’s α, to assess the degree of inter-
relatedness among the items of (sub) scales of the
instrument. Values between 0.70 and 0.95 are considered
adequate [21, 41].
Test-retest reliability [20] was assessed by calculating
the intraclass correlation coefficient (ICC), using a two-
way random effects model to compute absolute agree-
ment (single measures) [21, 42]. Values ≥0.70 are con-
sidered to be reliable [21]. Patients who completed the
three-month measure were assumed to be in a stable
physical state and were asked to complete the PROMs
again after 2 weeks.
Measurement error [20] was assessed by calculating the
standard error of measurement (SEM) using the formula:
√(σ2o + σ
2
residual) [22, 43]. Additionally, the smallest
detectable change on group level (SDC group) was calcu-
lated from the SDC at individual level (SDCindividual =
1.96*√2*SEM), using the formula: SDCindividual/√n [44].
Responsiveness
Responsiveness should be determined in a population
that shows actual change [20]. First, we assessed the
change scores of both measures between T0 and T3.
Second, we evaluated the occurrence of complications
(defined as grade 1 to 5 according to the Clavien-Dindo
classification) in relation to the change scores of both
measures between T0 and T3. Third, we assessed the
correlation and effect size of change score of both mea-
sures with the change score of the EQ-VAS between T0
and T3. We used the EQ-VAS score as this might cover
a broader underlying concept of overall health than the
EQ-5D-5 L, which seems applicable for this population
considering the heterogeneous and multidimensional
character of BCa disease. If there is an actual change in
HRQOL, we assumed that the EQ-VAS score shows this
change. We constructed hypotheses about the change
scores between T0 and T3 of the BCI and FACT-Bl-Cys,
in comparison to the change scores of the EQ-VAS. We
expected that patients with an improved or decreased
EQ-VAS score (i.e. improvement or deterioration of ≥10
points), the BCI and FACT-Bl-Cys values also increased
or declined, respectively. Previous studies in other pa-
tient populations reported a minimal important change
(MIC) varying from 6.9 to 8.9 [45–48]. Based on these
MIC values we assumed that an EQ-VAS change of 10
points might indicate actual change. Pre-specified hy-
potheses regarding the correlations and effect sizes be-
tween changes were that in patients with an improved
or declined EQ-VAS score (i.e. plus or minus ≥10
points), we expected a) to find moderate correlations of
≥0.30 between change in EQ-VAS and the change in
BCI and FACT-Bl-Cys values; b) to find a larger effect
size, in comparison to patients that did not show a
change in EQ-VAS (i.e. plus or minus ≤5 points). We
analyzed the effect size between the changes by calculat-
ing Cohens d, using the formula: (T3mean-T0mean)/T0SD.
Results
Translation procedure
Conceptual rather than literal translation was leading to
preserve the original meaning of each item. There was
agreement between the forward and backward transla-
tions, and no cultural adaptions regarding translation
were made. Based on the cognitive interviews, two items
regarding the interpretation and meaning were discussed
with the authors (JG, CM, CW) and FACIT representa-
tives. First, we added one additional phrase “for men
only” (in Dutch: “alleen voor mannen”) to the beginning
of FACT-Bl-Cys item Bl5 “I am able to maintain an
erection”, as this item is specifically aimed at men. Ac-
cording to FACIT scoring instructions Bl5 was not in-
cluded in the scoring algorithm of the scale. Therefore,
adapting this item could not influence the total score.
Second, the BCI items where patients are asked about
their “urine loss” could be interpreted according to their
own specific situation. In case of a neobladder, stoma, or
own bladder questions about “urine loss” could be an-
swered as problems with catheterizing incontinence,
emptying the stoma bag or leakage from the stoma bag,
or urination, respectively.
Patient population
In total 260 patients completed the baseline measure (T0),
followed by 182 patients who completed the three-month
measure post-operatively (T3). The T3 evaluation was
completed at a mean of 106 days (SD:14 days). Sixty-two
patients participated in the test–retest measurement (T3
retest). The T3 retest was completed at a mean of 14 days
(SD:6 days) after T3. In Table 1 the characteristics of the
study population are shown. Of the 260 patients who
completed T0, the mean age was 67 years (SD:10 years),
207 (80%) were male, 177 (68%) were married, and 149
(57%) were retired. These characteristics were not notably
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different at T3. We did not find any major change scores
between T0 and T3 for both measures, as presented in
Table 2.
Floor and ceiling effects
Seven out of nine BCI domains showed a ceiling effect
(meaning few problems), while no floor effects were ob-
served (see Table 3). Most missing values were reported in
the BCI “sexual function” domain at T0; for 112 of 260
patients (43%) we could not calculate a domain score.
Regarding the FACT-Bl-Cys, no floor or ceiling effects
were detected (see Table 3). The FACT-EWB domain at
T3 was missing for 9 out of 182 patients (5%). For 13
out of 182 patients (7%) the FACT-Bl-Cys total score
could not be calculated since they did not complete all
items.
Validity
Face validity was considered to be good for both measures,
as they appeared to address all relevant aspects of HRQOL
in Dutch BCa adults treated with radical cystectomy.
Regarding content validity, interviewed patients expressed
an overall positive opinion regarding relevance and com-
prehensiveness of the measures and their evaluative pur-
poses. Nonetheless, one item of FACT-Bl-Cys (Bl1 “I have
trouble controlling my urine”) raised concerns by some re-
spondents, as patients with different bladder diversions
might interpret this differently (e.g. stoma, neobladder of
Table 1 Patient characteristics of the test and re-test groups
Baseline (T0, pre-operatively) 3 months (T3, post-operatively) Test-retest (T3 retest)a
Population size (n) 260 182 62
Age (years)
Mean ± SD 67 ± 10 67 ± 9 67 ± 8
Median (min-max) 68 (35–88) 68 (38–82) 67 (40–82)
Gender, n (%)
Women 53 (20%) 37 (20%) 14 (23%)
Men 207 (80%) 145 (80%) 48 (77%)
Type of surgery, n (%)
RARC 142 (55%) 99 (54%) 32 (52%)
ORC 112 (43%) 78 (43%) 30 (48%)
LRC 6 (2%) 5 (3%) 0 (0%)
Diversion type, n (%)
Own bladder 233 (90%) 0 (0%) 0 (0%)
Ileal conduit 11 (4%) 114 (63%) 45 (72%)
Neobladder 1 (0%) 33 (18%) 11 (18%)
Other 3 (1%) 31 (17%) 6 (10%)
Missing 12 (5%) 4 (2%) 0 (0%)
Preoperative chemotherapy (yes), n (%) 38 (15%) 28 (15%) 8 (13%)
Education, n (%)
Elementary school or less 22 (8%) 17 (9%) 3 (5%)
Secondary education 94 (36%) 67 (37%) 20 (32%)
Postsecondary education 116 (45%) 87 (48%) 36 (58%)
Missing 28 (11%) 11 (6%) 3 (5%)
Living status, n (%)
Married 177 (68%) 136 (75%) 51 (82%)
Other 83 (32%) 46 (25%) 11 (18%)
Employment status, n (%)
Pension 149 (57%) 108 (59%) 36 (58%)
Salaried employment 61 (24%) 44 (25%) 19 (31%)
Other 23 (9%) 19 (10%) 4 (6%)
Missing 27 (10%) 11 (6%) 3 (5%)
aTwo weeks after T3. RARC robot-assisted radical cystectomy, ORC open radical cystectomy, LRC laparoscopic-assisted radical cystectomy
Michels et al. Journal of Patient-Reported Outcomes            (2019) 3:62 Page 6 of 17
Ta
b
le
2
C
ha
ng
e
in
sc
or
es
be
tw
ee
n
T0
(b
as
el
in
e)
an
d
T3
(9
0
da
ys
po
st
-o
pe
ra
tiv
e)
of
th
e
m
ea
su
re
s
D
om
ai
ns
N
o.
of
ite
m
s
pe
r
do
m
ai
n
T0
Va
lid
po
pu
la
tio
n
(n
)a
T0
M
ea
n
(S
D
)
T0
M
ed
ia
n
(m
in
-m
ax
)
T3
Va
lid
po
pu
la
tio
n
(n
)a
T3
M
ea
n
(S
D
)
T3
M
ed
ia
n
(m
in
-m
ax
)
T0
-T
3
Va
lid
po
pu
la
tio
n
(n
)
M
ea
n
ch
an
ge
(S
D
)
M
in
-m
ax
SE
BC
I U
rin
ar
y
do
m
ai
n
12
22
3
81
.6
(1
8.
2)
86
.4
(7
–1
00
)
15
8
82
.9
(1
7.
6)
89
.6
(2
5–
10
0)
14
5
1.
7
(2
1.
5)
−
55
;6
0
1.
8
Fu
nc
tio
n
4
24
2
84
.8
(2
5.
1)
10
0.
0
(0
–1
00
)
14
4
74
.8
(3
3.
2)
10
0.
0
(0
–1
00
)
13
7
−
11
.0
(3
9.
6)
−
10
0;
10
0
3.
4
Bo
th
er
8
21
2
79
.1
(2
0.
7)
84
.4
(1
1–
10
0)
15
9
86
.6
(1
3.
0)
90
.6
(4
7–
10
0)
13
6
7.
6
(2
0.
4)
−
41
;7
5
1.
7
Bo
w
el
do
m
ai
n
10
23
9
86
.6
(1
4.
4)
91
.7
(3
4–
10
0)
17
0
81
.4
(1
6.
6)
86
.7
(1
8–
10
0)
16
0
−
5.
4
(1
8.
9)
−
79
;5
8
1.
5
Fu
nc
tio
n
4
23
4
86
.3
(1
5.
5)
91
.8
(1
5–
10
0)
16
3
83
.8
(1
7.
1)
87
.5
(6
–1
00
)
15
2
−
2.
5
(2
0.
3)
−
79
;6
5
1.
7
Bo
th
er
6
23
9
86
.7
(1
7.
0)
95
.8
(2
5–
10
0)
19
6
80
.0
(1
8.
5)
83
.3
(2
1–
10
0)
15
9
−
6.
5
(2
1.
3)
−
79
;6
3
1.
7
Se
xu
al
do
m
ai
n
12
15
7
49
.1
(1
9.
6)
51
.4
(9
–8
5)
64
37
.1
(1
7.
7)
37
.4
(3
–7
5)
52
−
15
.6
(1
9.
8)
−
62
;1
8
2.
8
Fu
nc
tio
n
7
14
8
33
.0
(1
9.
3)
31
.3
(0
–8
2)
52
22
.7
(1
6.
6)
25
.0
(0
–6
1)
42
−
14
.2
(1
8.
6)
−
52
;1
8
2.
9
Bo
th
er
5
20
0
67
.2
(3
0.
7)
75
.0
(0
–1
00
)
13
0
52
.0
(3
1.
0)
40
.0
(0
–1
00
)
11
6
−
13
.5
(3
7.
8)
−
10
0;
10
0
3.
5
FA
C
T-
Bl
-C
ys
FA
CT
-P
W
B
7
25
4
23
.5
(4
.6
)
25
.0
(7
–2
8)
18
0
24
.4
(3
.6
)
25
.0
(8
–2
8)
17
7
0.
5
(4
.5
)
−
16
;1
8
0.
34
FA
CT
-S
W
B
7
25
5
22
.0
(4
.4
)
22
.2
(0
–2
8)
17
7
21
.3
(4
.5
)
22
.0
(0
–2
8)
17
5
−
1.
0
(4
.6
)
−
24
;2
2
0.
35
FA
CT
-E
W
B
6
25
3
17
.8
(4
.8
)
19
.0
(0
–2
4)
17
3
20
.4
(3
.5
)
21
.0
(5
–2
4)
16
7
2.
8
(4
.1
)
−
8;
23
0.
32
FA
CT
-F
W
B
7
25
7
17
.7
(5
.8
)
18
.0
(0
–2
8)
17
5
19
.0
(4
.9
)
20
.0
(6
–2
8)
17
2
1.
1
(5
.0
)
−
14
;2
0
0.
38
Bl
-C
ys
do
m
ai
n
15
25
7
40
.7
(1
0.
0)
41
.8
(9
–6
0)
17
5
43
.9
(8
.0
)
45
.0
(1
1–
58
)
17
2
2.
5
(1
0.
3)
−
34
;2
8
0.
79
FA
CT
-B
l-C
ys
to
ta
ls
co
re
42
24
7
12
1.
8
(2
2.
3)
12
4.
0
(3
8–
16
8)
16
9
12
9.
5
(1
8.
0)
13
2.
0
(4
7–
16
3)
16
1
5.
7
(1
9.
0)
−
55
;7
1
1.
5
EQ
-5
D
EQ
-5
D
-5
L
5
24
5
0.
80
(0
.1
)
0.
85
(0
–1
)
17
6
0.
84
(0
.1
3)
0.
88
(0
–1
)
16
7
0.
03
(0
.1
7)
−
1;
1
0.
1
EQ
-V
A
S
1
26
0
72
.0
(2
0.
5)
75
.0
(0
–1
00
)
22
9
74
.9
(1
9.
5)
80
.0
(0
–1
00
)
22
9
−
13
.5
(3
6.
9)
−
96
;8
1
2.
4
a T
he
nu
m
be
r
of
pa
tie
nt
s
th
at
co
m
pl
et
ed
en
ou
gh
ite
m
s
to
ca
lc
ul
at
e
a
to
ta
ls
co
re
,P
W
B
Ph
ys
ic
al
w
el
l-b
ei
ng
do
m
ai
n,
SW
B
So
ci
al
/f
am
ily
w
el
l-b
ei
ng
do
m
ai
n,
EW
B
Em
ot
io
na
lw
el
l-b
ei
ng
do
m
ai
n,
FW
B
Fu
nc
tio
na
lw
el
l-b
ei
ng
do
m
ai
n,
−
FA
C
T-
Bl
-C
ys
to
ta
ls
co
re
is
on
ly
ca
lc
ul
at
ed
w
he
n
al
li
te
m
s
ha
ve
be
en
co
m
pl
et
ed
Michels et al. Journal of Patient-Reported Outcomes            (2019) 3:62 Page 7 of 17
Ta
b
le
3
Re
lia
bi
lit
y
pr
op
er
tie
s
of
th
e
BC
I(
T0
,b
as
el
in
e)
an
d
FA
C
T-
Bl
-C
ys
(T
3,
90
da
ys
po
st
-o
pe
ra
tiv
e)
D
om
ai
ns
Po
pu
la
tio
n
si
ze
(n
)
Va
lid
po
pu
la
tio
n
(n
)a
N
o.
of
ite
m
s
pe
r
do
m
ai
n
M
in
im
al
no
.o
f
m
is
si
ng
ite
m
s
(%
)b
M
ax
im
al
no
.o
f
m
is
si
ng
ite
m
s
(%
)c
M
ea
n
(S
D
)
M
ed
ia
n
(m
in
-m
ax
)
Fl
oo
r
ef
fe
ct
C
ei
lin
g
ef
fe
ct
In
te
rn
al
co
ns
is
te
nc
y
(C
ro
nb
ac
h’
s
α)
T0
BC
I
U
rin
ar
y
do
m
ai
n
26
0
22
3
12
0
(6
6%
)
12
(3
%
)
82
(1
8)
86
(7
–1
00
)
0
(0
%
)
41
(1
6%
)
0.
83
Fu
nc
tio
n
26
0
24
1
4
0
(9
3%
)
4
(4
%
)
85
(2
5)
10
0
(0
–1
00
)
5
(2
%
)
14
4
(5
5%
)
0.
86
Bo
th
er
26
0
21
2
8
0
(6
7%
)
8
(4
%
)
79
(2
1)
84
(1
1–
10
0)
0
(0
%
)
48
(1
9%
)
0.
82
Bo
w
el
do
m
ai
n
26
0
23
9
10
0
(8
8%
)
10
(4
%
)
87
(1
5)
92
(3
4–
10
0)
0
(0
%
)
40
(1
5%
)
0.
83
Fu
nc
tio
n
26
0
23
4
4
0
(9
0%
)
4
(4
%
)
86
(1
5)
92
(1
5–
10
0)
0
(0
%
)
92
(3
5%
)
0.
70
Bo
th
er
26
0
23
9
6
0
(9
0%
)
6
(4
%
)
87
(1
7)
96
(2
5–
10
0)
0
(0
%
)
73
(3
5%
)
0.
77
Se
xu
al
do
m
ai
n
26
0
15
7
12
0
(4
2%
)
12
(1
2%
)
49
(2
0)
51
(9
–8
5)
0
(0
%
)
0
(0
%
)
0.
91
Fu
nc
tio
n
26
0
14
8
7
0
(4
5%
)
7
(1
2%
)
33
(1
9)
31
(0
–8
2)
5
(2
%
)
0
(0
%
)
0.
90
Bo
th
er
26
0
20
0
5
0
(6
9%
)
5
(1
5%
)
67
(3
1)
75
(0
–1
00
)
5
(2
%
)
61
(2
4%
)
0.
85
T3
FA
C
T-
Bl
-C
ys
FA
CT
-P
W
B
18
2
18
0
7
0
(9
1%
)
6
(1
%
)
24
(4
)
25
(0
–2
8)
0
(0
%
)
25
(1
4%
)
0.
80
FA
CT
-S
W
B
18
2
17
7
7
0
(6
3%
)
7
(2
%
)
21
(4
)
22
(0
–2
8)
2
(1
%
)
11
(6
%
)
0.
81
FA
CT
-E
W
B
18
2
17
3
6
0
(9
2%
)
6
(4
%
)
20
(3
)
21
(5
–2
4)
0
(0
%
)
1
(1
%
)
0.
77
FA
CT
-F
W
B
18
2
17
5
7
0
(9
0%
)
7
(4
%
)
19
(5
)
20
(6
–2
8)
1
(1
%
)
1
(1
%
)
0.
85
Bl
-C
ys
do
m
ai
n
18
2
17
5
15
0
(6
3%
)
15
(4
%
)
44
(8
)
45
(1
1–
58
)
0
(0
%
)
0
(0
%
)
0.
77
FA
CT
-B
l-C
ys
to
ta
l−
18
2
16
9
42
–
–
12
9
(1
8)
13
2
(7
4–
16
3)
0
(0
%
)
0
(0
%
)
0.
90
a T
he
nu
m
be
r
of
pa
tie
nt
s
th
at
co
m
pl
et
ed
en
ou
gh
ite
m
s
to
ca
lc
ul
at
e
a
to
ta
ls
co
re
,b
M
in
im
al
nu
m
be
r
of
m
is
si
ng
s
pe
r
do
m
ai
n
(i.
e.
67
%
m
is
se
s
0
ite
m
s)
,c
M
ax
im
al
nu
m
be
r
of
m
is
si
ng
s
pe
r
do
m
ai
n
(i.
e.
3%
m
is
se
s
12
ite
m
s)
,
PW
B
Ph
ys
ic
al
w
el
l-b
ei
ng
do
m
ai
n,
SW
B
So
ci
al
/f
am
ily
w
el
l-b
ei
ng
do
m
ai
n,
EW
B
Em
ot
io
na
lw
el
l-b
ei
ng
do
m
ai
n,
FW
B
Fu
nc
tio
na
lw
el
l-b
ei
ng
do
m
ai
n,
−
FA
C
T-
Bl
-C
ys
to
ta
ls
co
re
is
on
ly
ca
lc
ul
at
ed
w
he
n
al
li
te
m
s
ha
ve
be
en
co
m
pl
et
ed
Michels et al. Journal of Patient-Reported Outcomes            (2019) 3:62 Page 8 of 17
bladder replacement). We discussed these findings with
FACIT representatives, and decided that patients could re-
spond to this item in any way they feel appropriate.
The CFA was performed on the imputed datasets and
the model fit was evaluated based on Comparative Fit Index
(CFI), Tucker-Lewis index (TLI), Root Means Square Error
of Approximation (RMSEA), and Standardized Root Mean
Square Residual (SRMR). Considering structural validity for
BCI, the CFA resulted in a moderate fit (see Table 4). The
BCI in six factors showed a better fit (CFI:0.88, TLI:0.87,
RMSEA:0.06, SRMR:0.07) in comparison to three factors
(CFI:0.69, TLI:0.67, RMSEA:0.09, SRMR:0.09). Considering
structural validity for FACT-Bl-Cys, the CFA also resulted
in a moderate fit (see Table 4). For FACT-G in four factors,
the CFI was 0.88, the TLI was 0.86, the RMSEA was 0.05,
and the SRMR was 0.09. The Bl-Cys domain in three fac-
tors as proposed by Kim et al. [18] showed better fit (CFI:
0.85, TLI:0.81, RMSEA:0.06, SRMR:0.09). None of the hy-
pothesized factor structures for both PROMs fulfilled the
CFI or TLI thresholds of ≥0.95.
Considering hypotheses testing for BCI, 67% of prior
hypotheses (8 of 12) were confirmed (see Table 5).
Table 4 Structural validity properties of the BCI and FACT-Bl-Cys
CFI RMSEA SRMR TLI
T0 BCI
Three-factor structure (Gilbert et al. [13]) 0.69 0.09 0.09 0.67
1. Urinary domain (12 items)
2. Bowel domain (10 items)
3. Sexual domain (12 items)
Six-factor structure (Hever et al. [16]) 0.88 0.06 0.06 0.87
1. Urinary function (4 items)
2. Urinary bother (8 items)
3. Bowel function (4 items)
4. Bowel bother (6 items)
5. Sexual function (7 items)
6. Sexual bother (5 items)
T3 FACT-Bl-Cys
FACT-G in four-factor structure (27 items) 0.88 0.05 0.09 0.86
1. PWB Physical well-being domain (7 items)
2. SWB Social/family well-being domain (7 items)
3. EWB Emotional well-being domain (6 items)
4. FWB Functional well-being domain (7 items)
Bl-Cys domain in three-factor structure (Anderson et al. [11]) 0.75 0.07 0.11 0.70
1. C2 Losing weight; C3 Bowel control; C4 Diarrhea; C6 Good
appetite; ITU6 Embarrassed my condition; ITU1 Comfortable
discussing with friends (6 items)
2. C7 Content with appearance; ITU3 Limit social interactions; ITU4
Limit physical activity; ITU5 Limit sexual activity (4 items)
3. Bl1 Trouble controlling urine; ITU7 Condition wakes me up at night;
C9 Caring for condition difficult; VC1 Satisfied with urinary condition;
ITU2 I am afraid to be far from a toilet (5 items)
Bl-Cys domain in three-factor structure (Kim et al. [18]) 0.85 0.06 0.09 0.81
1. C2 Losing weight; C4 Diarrhea; Bl1 Trouble controlling urine; ITU7
Condition wakes me up at night; ITU6 Embarrassed my condition; C9
Caring for condition difficult; ITU2 I am afraid to be far from a toilet (7 items)
2. C3 Bowel control; C6 Good appetite; C7 Content with appearance;
ITU1 Comfortable discussing with friends; VC1 Satisfied with urinary
condition (5 items)
3. ITU3 Limit social interactions; ITU4 Limit physical activity; ITU5 Limit
sexual activity (3 items)
The CFA was performed using imputed data. CFI comparative fit index, RMSEA root mean square error of approximation; SRMR standardized root mean square
residual, TLI Tucker-Lewis index, The criteria for unidimensionality include CFI ≥ 0.95, TLI ≥ 0.95, RMSEA≤0.06, and SRMR≤0.08
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Correlations among the three BCI domains were ex-
pected to be low, however we found a moderate correl-
ation between the urinary domain and the bowel
domain (r = 0.35). Although we expected moderate cor-
relations when comparing the urinary domain with
FACT-G, the sexual domain with EQ-5D-5 L, and the
sexual domain with EQ-VAS, we instead found low cor-
relations of r = 0.29, r = 0.24, r = 0.28, respectively. For
FACT-Bl-Cys, 92% of all a priori hypotheses (12 of 13)
were confirmed (see Table 5). As hypothesized for
FACT-Bl-Cys, we found moderate correlations when
comparing the Bl-Cys domain with EQ-5D-5 L (r = 0.60),
FACT-Bl-Cys with EQ-5D-5 L (r = 0.70), and FACT-Bl-
Cys with EQ-VAS (r = 0.58). All correlations between
the five domains were moderate as expected, with the
exception of one low correlation was observed (EWB-
SWB r = 0.29).
Reliability
Internal consistency (Cronbach’s α), test–retest reliabil-
ity (ICC), and measurement error (SEM, SDC group,
SDC individual) are presented in Tables 3 and 6.
For BCI, Cronbach’s α of the domains ranged from 0.70
(“bowel function”) to 0.91 (sexual domain), which indi-
cates a good internal consistency. All ICCs were above
0.70, except for “sexual bother” which showed an ICC of
0.47. The SEM ranged from 4.17 (“sexual function”) to
20.07 (“sexual bother”), which resulted in a SDC individual
score ranging from 11.56 to 55.63. The SDC group ranged
from 1.90 (urinary domain) to 8.58 (“sexual bother”). Thus
for the domain “sexual bother”, an average group differ-
ence in score ≥ 8.58 cannot be attributed to only measure-
ment error, but actual change will have taken place.
For FACT-Bl-Cys, Cronbach’s α of the domains
ranged from 0.77 (Bl-Cys) to 0.85 (FWB), which
Table 5 Construct validity properties of the BCI and FACT-Bl-Cys
Correlation expected Hypotheses tested Correlation coefficient (r) Confirmed?
T0 BCI
Low (< 0.30) Correlations between 3 domains
are low
Urinary – Bowel 0.35 No
Urinary – Sexual 0.15 Yes
Bowel – Sexual 0.25 Yes
Moderate (0.30–0.69) Correlations between 3 domains
and FACT-G are moderate
FACT-G – Urinary 0.29 No
FACT-G – Bowel 0.39 Yes
FACT-G – Sexual 0.36 Yes
Correlations between 3 domains
and EQ-5D-5 L are moderate
EQ-5D-5 L – Urinary 0.34 Yes
EQ-5D-5 L – Bowel 0.38 Yes
EQ-5D-5 L – Sexual 0.24 No
Correlations between 3 domains
and EQ-VAS are moderate
VAS – Urinary 0.37 Yes
VAS – Bowel 0.32 Yes
VAS – Sexual 0.28 No
T3 FACT-Bl-Cys
Moderate (0.30–0.69) Correlations between 5 domains
are moderate
PWB – SWB 0.30 Yes
PWB – EWB 0.51 Yes
PWB – FWB 0.65 Yes
PWB – Bl-Cys 0.63 Yes
SWB – EWB 0.29 No
SWB – FWB 0.41 Yes
SWB – Bl-Cys 0.35 Yes
EWB – FWB 0.59 Yes
EWB – Bl-Cys 0.50 Yes
FWB – Bl-Cys 0.64 Yes
Correlation between Bl-Cys domain
and EQ-5D-5 L is moderate
Bl-Cys domain – EQ-5D-5 L 0.60 Yes
Correlation between total FACT-Bl-Cys
and EQ-5D-5 L / EQ-VAS are moderate
FACT-Bl-Cys total score – EQ-5D-5 L 0.70 Yes
FACT-Bl-Cys total score – VAS 0.58 Yes
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indicates a good internal consistency. All ICCs were
above 0.70, except for SWB which showed an ICC of
0.43. The SEM ranged from 1.57 (EWB) to 3.14 (Bl-Cys
domain), which resulted in a SDC individual score ran-
ging from 4.36 to 8.69. Our SDC individual values show
that, to determine a treatment effect a difference of at
least 4.36 to 8.69 points between two scores from an in-
dividual patient is required to ensure that the difference
is not attributed to measurement error. The SDC group
ranged from 0.59 (EWB) to 1.18 (Bl-Cys). See Additional
file 1 for separate variance components.
Responsiveness
Our total study population did not show major changes
between T0 and T3 for the BCI and FACT-Bl-Cys (see
Table 2). When evaluating the occurrence of complica-
tions, it appeared that our dataset at the time contained
too few registered complications to assess responsive-
ness, see Additional file 2. Only 42 patients had at least
one registered complication (Clavien-Dindo classifica-
tion grade 1 or higher). The number of patients that
completed enough items to calculate a total score ranged
from 0 to 27, depending on the domain.
Additionally, the change score between T0 and T3 of BCI
and FACT-Bl-Cys in comparison to the change score of the
EQ-VAS was studied. As presented in Additional file 3,
mean change scores between T0 and T3 were calculated
for patients who showed an improvement in the EQ-VAS
score of ≥10 points (n = 55, mean change:25, SD:16) or a
deterioration in this score of ≥10 points (n = 89, mean
change:-50, SD:30).
For BCI, the number of patients with an improved
EQ-VAS ranged from 17 to 47, depending on the do-
main. We hypothesized to find a larger effect size in the
improved group compared to the no-change group, but
only 1 of 9 hypotheses was confirmed (see Table 7). We
only found a larger effect size for the urinary domain in
the improved group, in comparison to the no-change
group (Cohens d: 0.36 > 0.06). Regarding hypotheses on
correlations, only 22% of all a priori hypotheses (2 of 9)
were confirmed. We only found the expected moderate
correlations for the change score of the bowel domain
(r = 0.42) and the “bowel bother” domain (r = 0.39).
For BCI, the number of patients with a deteriorated EQ-
VAS ranged from 10 to 40, depending on the domain.
Regarding hypotheses on effect sizes for the deterioration
group, only 3 out of 9 hypotheses were confirmed. We
found larger effect sizes in the urinary domain (Cohens d:
0.44 > 0.06), “urinary function” (Cohens d: − 0.56 > − 0.45),
and the sexual domain (Cohens d: − 1.10 > − 0.85). Re-
garding hypotheses on correlations, only 11% of all a priori
hypotheses (1 of 9) were confirmed. We only found a
moderate correlation for the change score of the “sexual
function” domain.
For FACT-Bl-Cys, the number of patients with an im-
proved EQ-VAS ranged from 45 to 52, depending on the
domain. For both effect sizes and correlations, 83% of all
a priori hypotheses (5 of 6) were confirmed. Only for
FACT-SWB we found a smaller effect size (Cohens d: −
0.17 < − 0.50) and a low correlation (r = 0.20).
For FACT-Bl-Cys, the number of patients with a dete-
riorated EQ-VAS ranged from 40 to 42, depending on
the domain. Regarding hypotheses on effect sizes for the
deterioration group, 67% of all a priori hypotheses (4 of
6) were confirmed (see Table 7). We found lower effect
sizes in the FACT-SWB (Cohens d: 0.00 < -0.50) and
FACT-EWB (Cohens d: 0.25 < 0.60). Regarding hypoth-
eses on correlations, 83% of all a priori hypotheses (5 of
6) were confirmed. We only found a low correlation for
the change in FACT-SWB (r = 0.24), which was contrary
to our expectations. Overall, these results indicate that
the FACT-Bl-Cys total score seems responsive to change
in generic HRQOL.
Discussion
The aim of this study was to translate two disease-spe-
cific measures (BCI and FACT-Bl-Cys) into Dutch and
to evaluate their measurement properties according to
the COSMIN criteria. Both measures were found to be
reliable and have good content validity, but limited
structural validity. This study showed that the Dutch
version of the BCI was not very responsive to changes in
generic HRQOL, and showed a ceiling effect. In the
Dutch version of the FACT-Bl-Cys no floor or ceiling ef-
fects were observed and the FACT-Bl-Cys total score
was responsive to changes in generic HRQOL.
The structural validity of the BCI was assessed as
moderate, as the hypothesized domains based on the ori-
ginal validation [13] and translational study [16] could
partially be confirmed. For BCI, we found a better fit for
a six-factor than a three-factor structure, which could
indicate that BCI distinguishes function and bother. The
structural validity of the FACT-Bl-Cys was assessed as
moderate as the majority of hypothesized domains could
not be confirmed. This limited fit could be caused by
the heterogeneous characteristics of BCa disease, as
many different topics are covered in the domains. The
FACT-Bl-Cys domains contain a wide range of com-
plaints that do not necessarily relate to each other. For
instance, the Bl-Cys domain contains items related to
body image, physical functioning, satisfaction, and so-
cials aspects. Future exploration of whether there is a
more adequate component solution is recommended for
further research.
Although experts debate on the minimum number of
patients needed for a factor analysis (ranging from 100
to 300 patients) [49–54], COSMIN advises to use a sam-
ple size of 7 patients per item, with a minimum number
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of 100 patients [38]. Though we handled the missing
data with multiple imputation in order to perform the
CFA with an adequate sample size, when interpreting
the results it should be considered that due to multiple
imputation, in which missing values are imputed with
the assumption that the distribution of the missing
values is similar to the observed data (i.e. predictive
mean matching approach), indices might be overfitted.
Regarding BCI at T0, high ceiling effects were observed
for both urinary and bowel domains. The maximum
scores indicate good function and no bother, which might
be when patients are recently diagnosed and have minor
symptoms (e.g. painless hematuria). Similar findings are
reported in previous studies [13, 16, 17].
Regarding FACT-Bl-Cys, there were uncertainties con-
cerning the calculation of total scores, as we excluded
the items BL4 ‘I am interested in sexual activity’ and
BL5 ‘I am able to have and maintain an erection’, ac-
cording to FACIT instructions. These items were also
not included in the CFA. Previously published studies
each handled these items differently [11, 12, 18, 19].
In comparison to previous BCI [13, 16, 17] and FACT-
Bl-Cys [11, 18, 19] studies, we found similar internal
consistency values for all domains. Reliability of both mea-
sures in terms of test-retest scores was good. To our
knowledge, the SEM and SDC have not yet been assessed
before for both measures. It should be noticed that our
design methodologically differs from previous conducted
studies. Previous FACT-Bl-Cys studies [11, 12, 18, 19]
assessed test-retest reliability using an interval of 4 weeks,
while COSMIN advises to use an interval of 2 weeks [38].
Additionally, FACT-Bl-Cys was completed at different
moments (e.g. 7 months to 3 years post-operatively)
[11, 12, 18, 19]. Anderson et al. did not show an ICC,
but reported a test-retest Spearman correlation of 0.89
for the Bl-Cys domain [11]. Three other studies re-
ported an ICC of 0.79 [12], 0.75 [19], and 0.82 [18] for
the Bl-Cys domain, which is similar to our ICC of 0.82.
Regarding construct validity of the BCI, our results
confirm the suggestion that the BCI captures additional
information which is not covered by generic instru-
ments. Schmidt et al. found similar results as they re-
ported low to moderate correlations (range: 0.16–0.48)
between BCI and the SF-36 [17]. Regarding construct
validity of the FACT-Bl-Cys, only Kim et al. correlated
FACT-Bl-Cys with a generic measure [18]. They found
moderate correlations (range: 0.29–0.69) between
FACT-Bl-Cys and the SF-36 [18]. These results are com-
parable to our moderate correlations between FACT-Bl-
Cys and the generic measures. In contrast to our results,
three previous studies showed a low correlation (range:
0.16–0.24) between SWB and Bl-Cys domain [12, 18, 19].
Cookson et al. suggested that this low correlation reflects
the predominant focus on physical/functional aspects of
HRQOL in the FACT-Bl-Cys [12]. We found moderate
correlations between all four domains (PWB, SWB, EWB,
FWB) and the Bl-Cys domain, which indicates an equal
share in HRQOL.
Only one BCI study mentioned responsiveness [17]. In
2014, Schmidt et al. reported an improvement 12
months after treatment for the urinary domain (Cohens
d: 0.38) and “urinary bother” (Cohens d: 0.53). Based on
these findings, the authors concluded that the BCI is re-
sponsive [17]. In 2018, a systematic review performed by
Mason et al., however, rated the BCI responsiveness as
unknown because Schmidt et al. only calculated effect
sizes and did not construct hypotheses a priori which is
not conform COSMIN recommendations [4].
We found one study that reported on longitudinal
changes of FACT-Bl-Cys [11]. Anderson et al. evaluated
change in 190 patients who underwent a radical cystec-
tomy (pre-operative and 12months post-operative) [11].
Authors did not calculate an effect size or correlations
regarding responsiveness according to COSMIN, but
they reported that patients with an ileal conduit diver-
sion had an average 5 points higher score at 12 months,
than those with an orthotopic neobladder diversion.
Strengths and limitations
As far as we are aware, this is the first study determining
the measurement properties of BCI and FACT-Bl-Cys,
according to COSMIN guidelines, in a large study popu-
lation. COSMIN enhances clarity and stimulates uniform
usage of terminology, enables researchers to evaluate
each measurement property individually, and improves
comparability with other studies.
This study also has some limitations. First, our study
population comprised only patients treated with radical
cystectomy. Therefore, we were unable to determine
whether both measures will be valid and reliable in a
more generic BCa population. Second, due to our study
design test-retest and measurement error had to be de-
termined at 3 months (T3, post-operatively) rather than
at baseline (T0, pre-operatively). For FACT-Bl-Cys this
is an adequate moment, but for BCI this might result in
a bias since this measure is originally intended for BCa
patients in general. Third, to explore responsiveness we
studied the correlation and effect size of change score of
both measures with the change score of the EQ-VAS be-
tween T0 and T3. Although we expected that radical
cystectomy impacts HRQOL, the BCI and FACT-Bl-Cys
did not detect large changes between T0 and T3. Two
previous studies did also not find major changes be-
tween T0 and T3 for FACT-Bl-Cys [55, 56]. This small
change could indicate that radical cystectomy does not
impact HRQOL largely, but it is also possible that the
BCI and FACT-Bl-Cys do not adequately detect the ac-
tual impact and change over time. Particularly since we
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did find a large change in EQ-VAS scores: the popula-
tion with an improved EQ-VAS score (n = 55) showed a
mean increase of 25 points, and the population with a
deteriorated EQ-VAS score (n = 89) showed a mean
decrease of 50 points. Previous studies in other patient
populations reported MIC values varying from 6.9 to 8.9
[45–48], but comparability between these different pop-
ulations should be considered. The FACT-Bl-Cys ap-
peared to be responsive to changes in generic HRQOL,
though limited structural validity must be considered as
this could negatively impact the responsiveness of spe-
cific domains. The possibility remains that in some cases
responsiveness was not detected, because there was no
meaningful change. In our study population we found
too few registered complications to assess responsiveness
based on the occurrence of complications. This study
was a first exploration of responsiveness of both mea-
sures, further research is warranted to evaluate whether
the BCI and FACT-Bl-Cys are responsive to objective
measures of change (e.g. occurrence of complications).
Clinical implications
Based on this study, both measures seem suitable for
cross-sectional use in clinical practice and for research
purposes. Consulted urologists mentioned that all topics
of both measures are usually discussed with patients in
clinical practice, and usage of measures could be valu-
able for clinicians in order to provide more personalized
care. Additionally, urologists noticed that the measures
seem quite long for daily practice which limits the suit-
ability and feasibility, but removing or combining items
influences validity.
When using the BCI, it should be considered that the
largest proportion of missing values was found in the
sexual domain, which is also noticed by two previous
studies [16, 17]. During cognitive interviews, some pa-
tients mentioned that the sexual domain items were
clear but ‘irrelevant’ as they had no sexual life. Thus a
‘never’ response or a missing value could indicate no
sexual bother or function, or the lack of activity. There-
fore, it is questionable whether BCI is suitable to meas-
ure “sexual function” and “sexual bother”. Patients also
indicated that BCI items about “urine loss” and FACT-
Bl-Cys items about “controlling my urine” could be
interpreted in different ways, as patients might have
different bladder diversions (e.g. stoma, neobladder of
bladder replacement). We recommend that future users
of the measures provide an instruction which states that
patients should answer these items according to their
own specific situation.
Conclusion
The Dutch versions of the BCI and FACT-Bl-Cys were
shown to be reliable and have good content validity.
Structural validity was limited for both measures. Only
the FACT-Bl-Cys total score was responsive to changes
in generic HRQOL. Despite some limitations, both mea-
sures are suitable for cross-sectional use in clinical prac-
tice and for research purposes. Exploration of a more
adequate component solution and whether both PROMs
are responsive when objective measures (e.g. occurrence
of complications) are used as an indicator of change,
needs to be further evaluated in future research.
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